Usando inhibidores de PARP en el tratamiento de las pacientes con cáncer de ovario: Cómo, Cuando, A quién y Por qué

4 / 21

Skipping Cisplatin-Based chemotherapy:
Single-Agent Therapy in Relapsed High Grade Ovarian Cancer: An Alternative?
Study Investigational drug Phase Patient populations
Study 42
NCT01078662 Olaparib II Patients with a germline BRCA mutated advanced ovarian cancer
who have received ≥3 prior lines of chemotherapy
Study 10 and
ARIEL 2 combined
analysis
NCT01482715 and
NCT01891344
Rucaparib II Patients with a germline or somatic BRCA mutated advanced
ovarian cancer who have received ≥2 prior lines of chemotherapy
QUADRA Study
NCT02354586 Niraparib II Patients with high-grade serous epithelial ovarian regardless BRCA
who have received 3 or more prior chemotherapy regimens
Kaufman B et al. J Clin Oncol. 2014;33:244–250; Domchek SM et al. Gynecol Oncol. 2016;140:199–203; 3. Kristeleit RS et al ESMO 2016; Abstract 856O;
Oza AM et al. Gynecol Oncol. 2017;147:267–275; Moore KN, et al. J Clin Oncol 2018;36(Suppl 15):Abstract 5514.